Lumos Pharma Inc. logo

Lumos Pharma (LUMO) stock

LUMO · Lumos Pharma Inc. · NASDAQ

Website

What is the latest news on LUMO stock?

PRago
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

All LUMO news

When does Lumos Pharma report earnings?

Lumos Pharma last reported on Aug 1, 2024, the date it announced on Jul 23, 2024. Before that it reported on May 15, 2024 and Mar 7, 2024.

LUMO earnings history

Latest news

25 items

Lumos Pharma Inc. (LUMO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for LUMO in the last 30 days. The most recent was published Apr 9, 2025.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.

LUMO FAQ

7 questions
  • What does Lumos Pharma Inc. do?
    Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
  • Where does LUMO stock trade?
    Lumos Pharma Inc. (LUMO) is listed on NASDAQ.
  • What sector and industry is LUMO in?
    Lumos Pharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Lumos Pharma Inc. go public?
    Lumos Pharma Inc. (LUMO) completed its IPO in 2011.
  • What are analysts saying about LUMO?
    Lumos Pharma Inc. has had 2 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $28.00 price target on 2021-11-04. Recent price targets range from $27.00 to $28.00.
  • What companies are similar to LUMO?
    Notable peers in the same industry include ABT (Abbott Laboratories), JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare LUMO side-by-side with any of them on Quantisnow.
  • How can I track LUMO on Quantisnow?
    Quantisnow aggregates Lumos Pharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LUMO to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change